Real-World experience of tyrosine kinase inhibitors in patients with Desmoid-type-Fibromatosis

Principle Investigator
Jonathan Noujaim
Date Approved
January 06, 2022
The use of Imatinib, Sorafenib and Pazopanib in the treatment of desmoid tumours has increased since the original trial was published a few years ago. The aim of this project is to add to the literature regarding real - world Canadian experience of tyrosine kinase inhibitors in patients with desmoids.

 
Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119] - ScienceDirect
View All Active Projects